Hepatitis A

The incidence of hepatitis A in New Zealand has decreased sharply since the 1960s, and currently about half the cases notified have a history of overseas travel.

More detailed epidemiological information is available on the Institute of Environmental Science and Research (ESR) surveillance website.

Further information on foodborne illness is available on the Ministry for Primary Industries website.

Following a prodrome that may include fever, malaise, anorexia, nausea or abdominal discomfort, there is jaundice, and sometimes an enlarged tender liver. Infection may be indicated by the presence of elevated serum aminotransferase levels. Children are often asymptomatic and occasionally present with atypical symptoms, including diarrhoea, cough, coryza or arthralgia. Jaundice is very unusual in children younger than 4 years, and 90 percent of cases in the 4–6 years age group are anicteric.

Laboratory definitive evidence for a confirmed case requires one of the following:

• detection of HAV nucleic acid
• in the absence of HAV vaccination in the preceding 12 weeks:
  • detection of anti-HAV IgM
  • seroconversion between paired sera tested in the same laboratory (in the absence of recent vaccination).

Samples from confirmed cases should be sent to ESR for genotyping and sequencing (preferably faecal and blood samples)

• Under investigation: A case that has been notified, but information is not yet available to classify it as probable or confirmed.
• Probable: A clinically compatible illness that is epidemiologically linked to a confirmed case.
• Confirmed: A clinically compatible illness accompanied by laboratory definitive evidence.
• Not a case: A case that has been investigated and subsequently found not to meet the case definition.

Humans and possibly certain non-human primates.

15–50 days, commonly 28–30 days.

Mainly person to person by the faecal-oral route.

Common-source outbreaks have been reported from contaminated water or food; foodborne outbreaks have been linked to an infected food handler, raw or undercooked shellfish harvested from contaminated water, and contaminated produce such as lettuce or berries. Transmission by injected drug use or sexual transmission is occasionally reported. Blood or blood-product transfusion related transmission (associated with a viraemic donor) is rare. Hepatitis A virus remains viable in the environment for long periods.

Maximum infectivity is during the 1–2 weeks before and the first few days after the onset of jaundice. Most cases are probably non-infectious after the first week of jaundice although prolonged viral excretion (up to 6 months) has been documented in infants and children. The period of communicability recommended for contact tracing purpose is 2 weeks before and 1 week after the onset of jaundice.

Attending medical practitioners or laboratories must immediately notify the local medical officer of health of suspected cases. Notification should not await confirmation.

See Appendix 5: Escalation pathways for more information

Obtain a history of travel (including overseas visitors within the incubation period), prior vaccination, possible contacts, consumption of shellfish or other suspect food (for example, overseas food), and blood or blood-product transfusion. Injecting drug users and men who have sex with men may be at higher risk of infection.

Ensure laboratory confirmation by serology has been attempted.

For all acute cases, diagnosed by positive IgM serology (in the absence of HAV vaccination in the preceding 12 weeks) or by detection of HAV by PCR/NAAT:

• patient serum and/or faecal specimens (preferably both) should be sent to Specimen Reception at ESR Kenepuru Science Centre, Porirua for HAV genotyping by the ESR Enteric, Environmental and Food Virology Laboratory.
• PHUs are requested to ensure these specimens are sent for genotyping

In health care facilities, only standard precautions are indicated for the majority of patients with hepatitis A. Infants, young children and incontinent patients require contact isolation precautions until at least 1 week after the onset of jaundice (or symptoms) or for the duration of hospitalisation.

Patients in high-risk groups (see the exclusion and clearance criteria in Appendix 2: Enteric disease) should stay away from work or school for at least 1 week from onset of jaundice or symptoms. In the case of schoolchildren, discuss with the school about availability of hand-cleaning facilities.

Advise the case and their caregivers of the nature of the infection and its mode of transmission.

Educate about hand hygiene and advise not to prepare or handle food for others until no longer considered infectious.

Identify contacts (household, sexual and other) for counselling about immunisation and/or immunoglobulin as appropriate. Contacts should be advised about possible symptoms, incubation period and the need to seek medical attention if unwell within the maximum incubation period of 50 days.

(Assessment of ‘close contact’ in an early childhood service will take into consideration: involvement with nappy changing, toilet hygiene practices and whether there has been more than one case associated with the service.)

1. Contact with a case during the latter half of the incubation period and until 1 week after onset of jaundice, including:
   • all household and sexual contacts
   • staff and children in close contact with the case at an early childhood service.
2. Those exposed to hepatitis A-contaminated food or water in a common-source outbreak.
3. Those exposed through food where the original reservoir remains unknown (eg, imported produce).
4. Exposure to potentially contaminated food via an infected food handler (refer to ‘Special situations’ below).

Laboratory screening of contacts is not usually indicated (see comment under ‘Vaccination’ below). Consider blood tests for any contact with compatible symptoms.

Nil unless symptoms develop.

There is reasonably broad international consensus that vaccine is effective for preventing secondary cases in healthy contacts, and it now tends to be the preferred option as opposed to immunoglobulin. Immunoglobulin may have higher efficacy, but this needs to be balanced against the advantages of vaccination, including ease of administration, duration of effect and the lack of interaction with live vaccines.

Age-appropriate vaccination is recommended for all close contacts over the age of 1 year. If time allows, consider pre-vaccine serology if there is a history or likelihood of previous hepatitis A vaccination or infection (for example, previous residence in an endemic country). Post-exposure prophylaxis (PEP) with vaccine should be offered to contacts as soon as possible, and within 2 weeks of last exposure to an infectious case. The efficacy of vaccine when administered > 2 weeks after exposure has not been established.

Where vaccine is contraindicated (or not immediately available), normal human immunoglobulin (NHIG) may be offered to a close contact who may have a reduced response to vaccine or has risk factors for severe disease. The dose of NHIG is 0.03 mL/kg given by intramuscular injection. PEP with NHIG should be offered to contacts as soon as possible, and within 2 weeks of last exposure to an infectious case. NHIG is available from the New Zealand Blood Service.

Close contacts under 1 year of age will require NHIG.

For further information refer to the medicine data sheets or the New Zealand Blood Service website.

If an outbreak occurs in an early childhood service, vaccination (and/or immunoglobulin if appropriate) may be indicated for all previously unimmunised staff and children at the service and unimmunised new staff and children for up to 6 weeks after the last case has been identified, including cases in the household of attendees. The number of infected cases should determine the extent of intervention.

Vaccination and/or immunoglobulin may also be indicated for adults and children at a school, hospital or custodial-care institution where an outbreak of hepatitis A is occurring. For sporadic cases in hospitals, schools or work settings, PEP is not routinely indicated, but careful hygiene practices should be maintained.

If a food handler is diagnosed with hepatitis A, vaccine (or immunoglobulin) should be given to other food handlers at the same premises. Vaccination of patrons is usually not needed but can be considered under the following conditions:

1. while infectious, the case directly handled uncooked foods or foods after cooking, and had diarrhoea or poor hygiene practices
2. vaccine (or immunoglobulin) may be given within 2 weeks of exposure.

Check for other cases in the community. Investigate potential food and water sources of infection only if there is a cluster of cases or an apparent epidemiological link.

If indicated, check water supply for microbiological contamination and compliance with the latest New Zealand drinking-water standards (Ministry of Health 2008). Liaise with the local territorial authority staff to investigate potential water sources of infection.

Clean and disinfect surfaces and articles soiled with stools. For further details, refer to Appendix 1: Disinfection.

If there is a cluster of cases, consider a media release and direct communication with local parents, early childhood services, schools and health professionals to encourage early reporting of symptoms. In communications with doctors, include recommendations regarding diagnosis, treatment and infection control.

In early childhood services or other institutional situations, ensure satisfactory facilities and practices regarding hand cleaning; nappy changing; toilet use and toilet training; preparation and handling of food; and cleaning of sleeping areas, toys and other surfaces.

Ensure complete case information is entered into EpiSurv.

Where food/food businesses are thought to be involved inform the Ministry for Primary Industries.

If a cluster of cases occurs, contact 0800GETMOH - CD option, and outbreak liaison staff at ESR, and complete the Outbreak Report Form.

• Ministry of Health. 2008. Drinking-water Standards for New Zealand 2005 (Revised 2008). Wellington: Ministry of Health.
• ACIP. 2007. Update: Prevention of hepatitis A after exposure to hepatitis A virus and in international travellers. Updated Recommendations of the Advisory Committee on Immunization Practices. Morbidity and Mortality Weekly Report 56(41): 1080–4.
• Crowcroft NS, Walsh B, Davison KL, et al. 2001. Guidelines for the control of hepatitis A virus infection. Communicable Disease and Public Health 4: 213–27.
• Health Protection Agency, UK. 2007. Immunoglobulin Handbook, Chapter 1 – Hepatitis A. London: Health Protection Agency.
• National Advisory Committee on Immunisation. 2000. Supplementary statement on hepatitis a vaccine. Canada Communicable Disease Report 26(ACS-4).
• Sagliocca L, Amoroso P, Stroffolini T, et al. 1999. Efficacy of hepatitis A vaccine in prevention of secondary hepatitis A infection: a randomised trial. Lancet 353: 340–1.
• Victor JC, Monto AS, Surdina TY, et al. 2007. Hepatitis A vaccine versus immune globulin for postexposure prophylaxis. New England Journal of Medicine 357(17): 1685–94.